Literature DB >> 3877968

Correlation of disease activity with circulating immune complexes (C1qbA) and complement breakdown products (C3D) in patients with systemic lupus erythematosus. A prospective study.

A J Swaak, J Groenwold, A Hannema, C E Hack.   

Abstract

Most biologic effects of immune complexes are mediated through the activation of the complement system. The relationship between lupus disease activity and the presence of C3 breakdown products (C3d) and circulating immune complexes (CIC) as demonstrated with the C1q binding assay (C1qbA), was evaluated. Nearly all 13 systemic lupus erythematosus (SLE) patients had a stable disease course in this prospective study, nevertheless, in each patient the profiles of the serologic parameters were quite different. Despite the small number of investigated patients (13), it is concluded that irrespective of the disease activity, the serologic parameters could be either positive or negative. No relationship could be obtained between disease activity and the presence of C3d and/or CIC. Nor was there any evidence that the presence of CIC would indicate increased levels of C3 breakdown products (C3d). This observation argues against a pathogenetic significance of CIC detected by the C1qbA in SLE. In conclusion, the supposed link between the presence of CIC, consumption and activation of the complement system, and the activity of SLE needs further study.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3877968     DOI: 10.1007/bf00541339

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  28 in total

1.  Complement breakdown products in plasma from patients with systemic lupus erythematosus and patients with membranoproliferative or other glomerulonephritis.

Authors:  L H Perrin; P H Lambert; P A Miescher
Journal:  J Clin Invest       Date:  1975-07       Impact factor: 14.808

2.  Deoxybonucleic acid (DNA) and antibodies to DNA in the serum of patients with systemic lupus erythematosus.

Authors:  E M Tan; P H Schur; R I Carr; H G Kunkel
Journal:  J Clin Invest       Date:  1966-11       Impact factor: 14.808

3.  Detection and characterization of DNA-anti-DNA complexes in a patient with systemic lupus erythematosus.

Authors:  C D Bruneau; J P Edmonds; G R Hughes; L Aarden
Journal:  Clin Exp Immunol       Date:  1977-06       Impact factor: 4.330

4.  Significance of persisting serologic abnormalities in SLE.

Authors:  R W Lightfoot; G R Hughes
Journal:  Arthritis Rheum       Date:  1976 Sep-Oct

5.  Correlation of disease activity and Clq-binding immune complexes with the neutrophil inclusions which form in the presence of SLE sera.

Authors:  E R Hurd; H E Jasin; J N Gilliam
Journal:  Clin Exp Immunol       Date:  1980-05       Impact factor: 4.330

6.  Detection of immune complexes in unheated sera by modified 125I-Clq binding test. Effect of heating on the binding of Clq by immune complexes and application of the test to systemic lupus erythematosus.

Authors:  R H Zubler; G Lange; P H Lambert; P A Miescher
Journal:  J Immunol       Date:  1976-01       Impact factor: 5.422

7.  The C1q binding assay in systemic lupus erythematosus: discordance with disease activity.

Authors:  R D Inman; J K Fong; B A Pussell; P J Ryan; G R Hughes
Journal:  Arthritis Rheum       Date:  1980-11

8.  Immunopathologic studies of systemic lupus erythematosus. II. Antinuclear reaction of gamma-globulin eluted from homogenates and isolated glomeruli of kidneys from patients with lupus nephritis.

Authors:  C Krishnan; M H Kaplan
Journal:  J Clin Invest       Date:  1967-04       Impact factor: 14.808

9.  Localization of fluorescein-labeled antinucleoside antibodies in glomeruli of patients with active systemic lupus erythematosus nephritis.

Authors:  G A Andres; L Accinni; S M Beiser; C L Christian; G A Cinotti; B F Erlanger; K C Hsu; B C Seegal
Journal:  J Clin Invest       Date:  1970-11       Impact factor: 14.808

10.  Correlation between levels of breakdown products of C3, C4, and properdin factor B in synovial fluids from patients with rheumatoid arthritis.

Authors:  L H Perrin; U E Nydegger; R H Zubler; P H Lambert; P A Miescher
Journal:  Arthritis Rheum       Date:  1977-03
View more
  4 in total

1.  Complement split product C3d as an indicator of disease activity in systemic lupus erythematosus.

Authors:  E Röther; B Lang; R Coldewey; K Hartung; H H Peter
Journal:  Clin Rheumatol       Date:  1993-03       Impact factor: 2.980

2.  The model of circulating immune complexes and interleukin-6 improves the prediction of disease activity in systemic lupus erythematosus.

Authors:  Chokchai Thanadetsuntorn; Pintip Ngamjanyaporn; Chavachol Setthaudom; Kenneth Hodge; Nisara Saengpiya; Prapaporn Pisitkun
Journal:  Sci Rep       Date:  2018-02-08       Impact factor: 4.379

Review 3.  Immune complexes as culprits of immunopathology in severe COVID-19.

Authors:  Philipp Kolb; Sebastian Giese; Reinhard Edmund Voll; Hartmut Hengel; Valeria Falcone
Journal:  Med Microbiol Immunol       Date:  2022-07-23       Impact factor: 4.148

4.  Susceptibility for Lupus Nephritis by Low Copy Number of the FCGR3B Gene Is Linked to Increased Levels of Pathogenic Autoantibodies.

Authors:  Johannes C Nossent; Andrea Becker-Merok; Maureen Rischmueller; Sue Lester
Journal:  Autoimmune Dis       Date:  2013-06-20
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.